CRBP
Corbus Pharmaceuticals Holdings, Inc.
$7.56
0.00%
$142.7M
No data for this timeframe.
Vol
Market Cap$142.7M
Cap SizeMicro Cap
Analyst ConsensusStrong Buy (94%)
Inst. Holders7 funds
Inst. Value$10.2M
Inst. Activity3 buys / 3 sells
Insider Activity2B / 3S
Insider Net $$4.5K
Reddit Sentiment40° Cool
SEC Reports11
Press Releases1
Recent Activity
Jun 3, 2026
Insider
Saxena Nishant C bought 9,000 shares
Chief Business Officer @ $7.58 ($68.2K)
Jun 2, 2026
Insider
Saxena Nishant C bought 4,500 shares
Chief Business Officer @ $7.33 ($33.0K)
May 27, 2026
short_volume
Short Volume: CRBP — 60.0% short (0.5M / 0.9M)
Short: 529,577 | Exempt: 54,330 | TRF Vol: 881,947 | Short Ratio: 60.0% | Off-exchange volume (dark
May 26, 2026
SEC
Corbus reported updated Phase 1/2 data for CRB-701, a next-generation Nectin-4 ADC, showing a 42.9% confirmed ORR in 2L
8-K — Impact 7/10
May 21, 2026
SEC
Corbus Pharmaceuticals appointed Nishant Saxena as its first Chief Business Officer with a two-year employment agreement
8-K — Impact 4/10
May 21, 2026
Insider
Saxena Nishant C sold 58,300 shares
Chief Business Officer @ $0.00 ($0.00)
May 14, 2026
SEC
Corbus Pharmaceuticals appointed Brent Pfeiffenberger to its Board of Directors and shareholders approved an amendment t
8-K — Impact 4/10
Inst.
VANGUARD GROUP INC — ADD
859,407 shares ($7.0M)
Price Targets
$36.50
+374.0% upside
Strong Buy
Current $7.70
Low $17.00
Median $37.00
High $54.00
10 analysts
$17.00
$54.00
Analyst Ratings
7Strong Buy
8Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 27, 2026 | Wedbush | MAINTAIN | Outperform → Outperform |
| May 26, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| May 22, 2026 | Mizuho | MAINTAIN | Outperform → Outperform |
| May 13, 2026 | Jefferies | MAINTAIN | Buy → Buy |
| May 13, 2026 | Oppenheimer | MAINTAIN | Outperform → Outperform |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-1.24 | $-1.38 — $-1.15 | 14% YoY | 10 |
| Next Q | $-1.03 | $-1.49 — $-0.63 | 46% YoY | 10 |
| Current FY | $-4.57 | $-5.70 — $-3.31 | 23% YoY | 10 |
| Next FY | $-5.07 | $-7.09 — $-2.55 | -11% YoY | 9 |
Latest Reports
BULLISH
8-K
7/10
Corbus reported updated Phase 1/2 data for CRB-701, a next-generation Nectin-4 ADC, showing a 42.9% confirmed ORR in 2L
May 26, 2026
NEUTRAL
8-K
4/10
Corbus Pharmaceuticals appointed Nishant Saxena as its first Chief Business Officer with a two-year employment agreement
May 21, 2026
MIXED
Press
6/10
Corbus Pharmaceuticals reported Q4 and full-year 2025 financial results with a wider net loss of $20.6M ($1.25/share) co
Mar 9, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $7.0M | ADD |
| RENAISSANCE TECHNOLOGIES LLC | $2.9M | DOUBLED |
| MORGAN STANLEY | $182.2K | NEAR_EXIT |
| TWO SIGMA INVESTMENTS, LP | $101.6K | TRIM |
| FMR LLC | $9.2K | TRIM |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 3, 2026 | Saxena Nishant | BUY | $68.2K |
| Jun 2, 2026 | Saxena Nishant | BUY | $33.0K |
| May 21, 2026 | Saxena Nishant | A | $0.00 |
| May 21, 2026 | Saxena Nishant | A | $0.00 |
| May 19, 2026 | Pfeiffenberger Brent | A | $0.00 |
Reddit Sentiment
40°
Cool
Bearish
Neutral
Bullish
7 institutional holders with $10.2M total value (1,249,767 shares) as of 2025-Q4. Top holders: VANGUARD, RENAISSANCE, MORGAN.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 859,407 | $7.0M | 68.8% | ADD +40.4% |
| 2 | RENAISSANCE TECHNOLOGIES LLC | 354,300 | $2.9M | 28.3% | DOUBLED +230.5% |
| 3 | MORGAN STANLEY | 22,381 | $182.2K | 1.8% | NEAR_EXIT -85.5% |
| 4 | TWO SIGMA INVESTMENTS, LP | 12,480 | $101.6K | 1.0% | TRIM -52.8% |
| 5 | FMR LLC | 1,129 | $9.2K | 0.1% | TRIM -56.8% |
| 6 | WELLS FARGO & COMPANY/MN | 44 | $358.00 | 0.0% | DOUBLED +4300.0% |
| 7 | BANK OF AMERICA CORP /DE/ | 26 | $212.00 | 0.0% | NEAR_EXIT -100.0% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| VANGUARD GROUP INC | ADD | 612,030 | 859,407 | +40.4% | $7.0M | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 107,200 | 354,300 | +230.5% | $2.9M | 2025-Q4 |
| MORGAN STANLEY | NEAR_EXIT | 154,842 | 22,381 | -85.5% | $182.2K | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 26,457 | 12,480 | -52.8% | $101.6K | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | DOUBLED | 1 | 44 | +4300.0% | $358.00 | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | NEAR_EXIT | 54,661 | 26 | -100.0% | $212.00 | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 153,539 | 107,200 | -30.2% | $1.4M | 2025-Q3 |
| UBS Group AG | TRIM | 91,843 | 59,496 | -35.2% | $752.6K | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 45,501 | 26,457 | -41.9% | $334.7K | 2025-Q3 |
| WELLS FARGO & COMPANY/MN | NEAR_EXIT | 251 | 1 | -99.6% | $15.00 | 2025-Q3 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | EXIT | 68,148 | 0 | -100.0% | $0.00 | 2025-Q3 |
| MORGAN STANLEY | DOUBLED | 76,611 | 158,999 | +107.5% | $1.1M | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 345,200 | 153,539 | -55.5% | $1.1M | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 16,579 | 71,893 | +333.6% | $496.1K | 2025-Q2 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 121,164 | 45,501 | -62.4% | $314.0K | 2025-Q2 |
| FMR LLC | TRIM | 3,371 | 1,455 | -56.8% | $10.0K | 2025-Q2 |
| WELLS FARGO & COMPANY/MN | NEAR_EXIT | 6,648 | 251 | -96.2% | $1.7K | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 139,100 | 345,200 | +148.2% | $1.8M | 2025-Q1 |
| CITADEL ADVISORS LLC | DOUBLED | 59,200 | 122,091 | +106.2% | $648.3K | 2025-Q1 |
| FMR LLC | DOUBLED | 152 | 3,371 | +2117.8% | $17.9K | 2025-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 16,000 | 139,100 | +769.4% | $1.6M | 2024-Q4 |
| UBS Group AG | DOUBLED | 24,215 | 89,377 | +269.1% | $1.1M | 2024-Q4 |
| MORGAN STANLEY | TRIM | 154,746 | 61,631 | -60.2% | $727.2K | 2024-Q4 |
| CITADEL ADVISORS LLC | TRIM | 130,400 | 59,200 | -54.6% | $698.6K | 2024-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 4,249 | 6,444 | +51.7% | $76.0K | 2024-Q4 |
9 unique insiders with 5 transactions. Net insider value: $4.5K ($101.2K bought, $96.7K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 3, 2026 | Saxena Nishant C | Chief Business Officer | BUY | 9,000 | $7.58 | $68.2K |
| Jun 2, 2026 | Saxena Nishant C | Chief Business Officer | BUY | 4,500 | $7.33 | $33.0K |
| May 21, 2026 | Saxena Nishant C | Chief Business Officer | A | 58,300 | $0.00 | $0.00 |
| May 21, 2026 | Saxena Nishant C | Chief Business Officer | A | 192,300 | $0.00 | $0.00 |
| May 19, 2026 | Pfeiffenberger Brent | Director | A | 24,700 | $0.00 | $0.00 |
| May 19, 2026 | Pfeiffenberger Brent | Director | A | 7,500 | $0.00 | $0.00 |
| May 19, 2026 | Jacques Rachelle Suzanne | Director | A | 3,800 | $0.00 | $0.00 |
| May 19, 2026 | Altmeyer Anne | Director | A | 3,800 | $0.00 | $0.00 |
| May 19, 2026 | Altmeyer Anne | Director | A | 12,300 | $0.00 | $0.00 |
| May 19, 2026 | Kung Winston | Director | A | 3,800 | $0.00 | $0.00 |
| May 19, 2026 | Jenkins John Kenneth | Director | A | 12,300 | $0.00 | $0.00 |
| May 19, 2026 | Ben Yong | Director | A | 3,800 | $0.00 | $0.00 |
| May 19, 2026 | Ben Yong | Director | A | 12,300 | $0.00 | $0.00 |
| May 19, 2026 | Jenkins John Kenneth | Director | A | 3,800 | $0.00 | $0.00 |
| May 19, 2026 | Jacques Rachelle Suzanne | Director | A | 12,300 | $0.00 | $0.00 |
| May 19, 2026 | Kung Winston | Director | A | 12,300 | $0.00 | $0.00 |
| Mar 2, 2026 | Smethurst Dominic | Chief Medical Officer | SELL | 6,097 | $8.30 | $50.6K |
| Feb 3, 2026 | Smethurst Dominic | Chief Medical Officer | SELL | 3,285 | $8.09 | $26.6K |
| Feb 3, 2026 | Hodgson Ian | Chief Operating Officer | SELL | 2,415 | $8.09 | $19.5K |
11 SEC filing reports analyzed. Sentiment: 2 bullish, 1 bearish, 2 mixed, 6 neutral. Avg impact: 5.1/10.
BULLISH
8-K
7/10
Corbus reported updated Phase 1/2 data for CRB-701, a next-generation Nectin-4 ADC, showing a 42.9%
May 26, 2026
NEUTRAL
8-K
4/10
Corbus Pharmaceuticals appointed Nishant Saxena as its first Chief Business Officer with a two-year
May 21, 2026
NEUTRAL
8-K
4/10
Corbus Pharmaceuticals appointed Brent Pfeiffenberger to its Board of Directors and shareholders app
May 14, 2026
MIXED
8-K
5/10
Corbus Pharmaceuticals reported Q1 2026 net loss of $23.0M ($1.23/share), slightly beating the $1.26
May 12, 2026
NEUTRAL
PRESS-RELEASE
4/10
Corbus reported Q1 2026 net loss of $23.0M ($1.23/share), slightly missing consensus EPS of -$1.22.
May 12, 2026
NEUTRAL
8-K
4/10
Corbus Pharmaceuticals renewed employment agreements with CEO Yuval Cohen and CFO Sean Moran, effect
Apr 16, 2026
NEUTRAL
8-K
4/10
Corbus Pharmaceuticals announced the last patient has completed their first visit in the CANYON-1 Ph
Apr 14, 2026
MIXED
8-K
6/10
Corbus Pharmaceuticals announced broad alignment with the FDA on the registration path for its oncol
Apr 7, 2026
NEUTRAL
EFFECT
4/10
Corbus Pharmaceuticals Holdings, Inc. (CRBP) has announced the effectiveness of a shelf registration
Mar 23, 2026
BEARISH
S-3
7/10
Corbus Pharmaceuticals filed an S-3 shelf registration, signaling potential future share issuance. T
Mar 11, 2026
BULLISH
8-K
7/10
Corbus Pharmaceuticals updated its corporate presentation with positive clinical data from its pipel
Feb 25, 2026
Current analyst consensus: Strong Buy (94% buy). Based on 16 analysts: 7 strong buy, 8 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$36.50 mean target
+374.0% upside
Strong Buy (1.11)
$17.00 Low
$54.00 High
| Metric | Value |
|---|---|
| Current Price | $7.70 |
| Target Low | $17.00 |
| Target Mean | $36.50 |
| Target Median | $37.00 |
| Target High | $54.00 |
| # Analysts | 10 |
| Recommendation | Strong Buy (1.11) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-1.24 | $-1.38 | $-1.15 | 14.1% | — | 0↑ 3↓ | $0.0B | 0.0% | 10 |
| Next Q 2026-09-30 |
$-1.03 | $-1.49 | $-0.63 | 45.6% | — | 3↑ 4↓ | $0.0B | 0.0% | 10 |
| Current FY 2026-12-31 |
$-4.57 | $-5.70 | $-3.31 | 22.6% | -0.2% | 4↑ 4↓ | $0.0B | 0.0% | 10 |
| Next FY 2027-12-31 |
$-5.07 | $-7.09 | $-2.55 | -11.1% | — | 2↑ 6↓ | $0.0B | 116.0% | 9 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-1.237 | |
| 7d ago | $-1.237 | -0.000 |
| 30d ago | $0.000 | -1.237 |
| 60d ago | $-1.236 | -0.001 |
| 90d ago | $-1.415 | +0.178 |
6 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 1 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 27, 2026 | Wedbush | MAINTAIN | Outperform | Outperform |
| May 26, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| May 22, 2026 | Mizuho | MAINTAIN | Outperform | Outperform |
| May 13, 2026 | Jefferies | MAINTAIN | Buy | Buy |
| May 13, 2026 | Oppenheimer | MAINTAIN | Outperform | Outperform |
| May 13, 2026 | Guggenheim | REITERATE | Buy | Buy |
| Apr 29, 2026 | Guggenheim | INITIATE | — | Buy |
| Mar 10, 2026 | Oppenheimer | MAINTAIN | Outperform | Outperform |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 7 | 8 | 1 | 0 | 0 | 94% | |
| May 1, 2026 | 7 | 8 | 1 | 0 | 0 | 94% | |
| Apr 1, 2026 | 6 | 9 | 1 | 0 | 0 | 94% | |
| Mar 1, 2026 | 6 | 9 | 1 | 0 | 0 | 94% | |
| Feb 1, 2026 | 6 | 9 | 1 | 0 | 0 | 94% | |
| Jan 1, 2026 | 6 | 9 | 1 | 0 | 0 | 94% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
40°
Cool
Bearish
Neutral
Bullish
1 mentions
0 bullish
1 bearish
1 time period
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Feb 26, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
Recent Reddit Threads
CRBP -- going to run up
▲ 1
💬 2
⚡ 0.0
May 27, 2026
short_volume
Short Volume: CRBP — 60.0% short (0.5M / 0.9M)
Short: 529,577 | Exempt: 54,330 | TRF Vol: 881,947 | Short Ratio: 60.0% | Off-exchange volume (dark pool + OTC)
May 26, 2026
fda
Corbus Pharmaceuticals Reports Updated CRB-701 Phase 1/2 Clinical Data Demonstrating Robust Activity in 2L Oropharyngeal and Cervical Cancers
<p align="justify">NORWOOD, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”)
May 13, 2026
other
Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences
<p align="justify">NORWOOD, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP), a clinical-stage company f
May 12, 2026
earnings
Corbus Pharmaceuticals Reports Q1 2026 Financial Results and Provides a Corporate Update
<p align="justify">NORWOOD, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”)
May 6, 2026
Clinical Trial
JBT-101 in Systemic Lupus Erythematosus (SLE)
Phase Phase 2 — COMPLETED
May 4, 2026
earnings_calendar
CRBP Q1 2026 Earnings Scheduled — 2026-05-04
Mar 9, 2026
earnings
Corbus Pharmaceuticals Reports Q4 and 2025 Financial Results and Provides a Corporate Update
<p align="justify">NORWOOD, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company
Mar 9, 2026
earnings_calendar
CRBP Q4 2025 Earnings After Market Close — 2026-03-09